• Citer

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.

par Colombo, M.L.;Fernández, I;Abdurakhmanov, Djamal;Ferreira, P A;Strasser, S I;Urbanek, P;Moreno, Christophe ;Streinu-Cercel, A.;Verheyen, A;Iraqi, W;Demasi, R;Hill, A;Läuffer, J M;Lonjon-Domanec, I;Wedemeyer, Heiner
Référence Gut
Publication Publié, 2013-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-α (PEG-IFNα) and ribavirin (RBV) in patients with advanced liver fibrosis caused by HCV genotype 1 (HCV-1).